This week's Fierce Biotech is brought to you by the Fierce BD&L Summit for Life Sciences. |
|
|
Dear E, The Fierce BD&L Summit for Life Sciences is the premier event that brings together hundreds of CEOs and business development professionals from leading pharmaceutical and biotech companies along with investors and venture capitalists. Join us March 14-15 in San Francisco to share best practices and discover the latest trends impacting life sciences deal-making. As a subscriber of Fierce Biotech, please enjoy a 15% discount on your registration. Register now and use promo code FB15 to save. Please note this discount can only be applied to new registrations. |
Don’t miss your opportunity to attend the top conference for deal making and cultivating connections. |
Featured Sessions The VC Perspective: Deal Drivers, Financing Options and Trends for 2023 - Understanding the different approaches taken by VCs for their financing models
- Looking at the biggest opportunities for growth
- What metrics and criteria are VCs looking at during their diligence process and what drives their decision making especially in the current economic climate?
- Vetting your VCs: Factors to take into consideration when deciding what route to take
|
|
|
Laura Berner
Chief Operating Officer
TRexBio |
| Seth Lieblich
Principal
8VC |
| Jennifer Friel Goldstein
Managing Partner, Life Sciences & Healthcare, SVB Capital
Silicon Valley Bank |
| |
|
Mariana Mihalusova, PhD, MBA
Vice President
Venrock |
| Christopher Mauney
Senior Associate
NovaQuest Capital Management |
| | |
|
Strategies for Survival: Looking at Alternative Deal Constructs and Creative Financing to Endure Market Instability - How do you decide what the “right” deal structure is for the collaboration?
- Using non-diluted funding, other non-equity financing or option-based deals to stay afloat
- Building flexibility into the deal structure to account for uncertainty
- Deciding whether to go the M&A route vs. alliances or product acquisition
- Going beyond the conventional: Examples of innovative deal structures: joint ventures, subsidiary programs, royalty financing and more
- Tips for structuring a deal that is win-win for both sides
|
|
|
Mark Stead
Senior Director in Business Development
Exelixis |
| Michael Bologna
Partner
NovaQuest Capital Management |
| Ahmed Mousa
Senior Vice President, Chief Business Officer and General Counsel
Pieris Pharmaceuticals |
| Ramlah Nehring, PhD
Head of Strategy and Transactions
Roche Diagnostics |
|
|
Featured Sessions Panel: The VC Perspective: Deal Drivers, Financing Options and Trends for 2023 - Understanding the different approaches taken by VCs for their financing models
- Looking at the biggest opportunities for growth
- What metrics and criteria are VCs looking at during their diligence process and what drives their decision making especially in the current economic climate?
- Vetting your VCs: Factors to take into consideration when deciding what route to take
|
Laura Berner
Chief Operating Officer
TRexBio |
Seth Lieblich
Principal
8VC |
Jennifer Friel Goldstein
Managing Partner, Life Sciences & Healthcare, SVB Capital
Silicon Valley Bank |
Mariana Mihalusova, PhD, MBA
Vice President
Venrock |
Christopher Mauney
Senior Associate
NovaQuest Capital Management |
Panel: Strategies for Survival: Looking at Alternative Deal Constructs and Creative Financing to Endure Market Instability - How do you decide what the “right” deal structure is for the collaboration?
- Using non-diluted funding, other non-equity financing or option-based deals to stay afloat
- Building flexibility into the deal structure to account for uncertainty
- Deciding whether to go the M&A route vs. alliances or product acquisition
- Going beyond the conventional: Examples of innovative deal structures: joint ventures, subsidiary programs, royalty financing and more
- Tips for structuring a deal that is win-win for both sides
|
Mark Stead
Senior Director in Business Development
Exelixis |
Michael Bologna
Partner
NovaQuest Capital Management |
Ahmed Mousa
Senior Vice President, Chief Business Officer and General Counsel
Pieris Pharmaceuticals |
Ramlah Nehring, PhD
Head of Strategy and Transactions
Roche Diagnostics |
Book Your Room Today! Special attendee discount ends February 13th
Hyatt Centric Fisherman's Wharf San Francisco 555 North Point Street
San Francisco, CA 94133 |
|
|
Book Your Room Today! Special attendee discount ends Feb.13th
Hyatt Centric Fisherman's Wharf San Francisco 555 North Point Street
San Francisco, CA 94133 |
| |
|
Thank You to Our 2023 Partners Platinum Partner |
|
|
Interested in partnering? |
| Complete the inquiry form here and a member of our team will follow up with you shortly! |
|
|
Interested in partnering?
Complete the inquiry form here and a member of our team will follow up with you shortly! |
|
|
If you no longer wish to receive promotion on this event, simply unsubscribe.
Refer to our Privacy Policy.
Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017 Contact Us
© 2023 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. |
|
|
|
